Gerald Proehl Net Worth

The estimated Net Worth of Gerald T Proehl is at least $6.13 ezer dollars as of 8 August 2024. Mr. Proehl owns over 1,666 units of Tenax Therapeutics Inc stock worth over $6,135 and over the last 11 years he sold TENX stock worth over $0. In addition, he makes $0 as Director at Tenax Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Proehl TENX stock SEC Form 4 insiders trading

Gerald has made over 4 trades of the Tenax Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 1,666 units of TENX stock worth $6,131 on 8 August 2024.

The largest trade he's ever made was buying 50,000 units of Tenax Therapeutics Inc stock on 24 June 2015 worth over $250,000. On average, Gerald trades about 4,577 units every 181 days since 2014. As of 8 August 2024 he still owns at least 1,667 units of Tenax Therapeutics Inc stock.

You can see the complete history of Mr. Proehl stock trades at the bottom of the page.

Gerald Proehl biography

Gerald T. Proehl is Director of Oxygen Biotherapeutics Inc. Mr. Proehl was recently the President and Chief Executive Officer of Santarus, Inc., a company that he helped to found in 1999, and where he led the sale of Santarus to Salix Pharmaceuticals for $2.6 billion in December of 2013. Prior to Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, where he served in various capacities, including Vice President of Global Marketing. During his career at Hoechst he worked across numerous therapeutic areas, including CNS, cardiovascular, and gastrointestinal. Mr. Proehl was recently appointed to the Board of Directors of Auspex Pharmaceuticals, Inc., a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases. He has also joined the Board of Directors of Sophiris Bio Inc., a publicly traded company developing a late-stage, targeted treatment for benign prostatic hyperplasia. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst University.

How old is Gerald Proehl?

Gerald Proehl is 59, he's been the Director of Tenax Therapeutics Inc since 2014. There are 7 older and 8 younger executives at Tenax Therapeutics Inc. The oldest executive at Tenax Therapeutics Inc is Ronald Blanck, 75, who is the Independent Chairman of the Board.

What's Gerald Proehl's mailing address?

Gerald's mailing address filed with the SEC is 101 GLEN LENNOX DRIVE, SUITE 300, , CHAPEL HILL, NC, 27517.

Insiders trading at Tenax Therapeutics Inc

Over the last 10 years, insiders at Tenax Therapeutics Inc have traded over $5,051 worth of Tenax Therapeutics Inc stock and bought 571,282 units worth $853,236 . The most active insiders traders include Capital, Llc Armistice Capi..., Declan Doogan és Stuart Rich. On average, Tenax Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $1,664,103. The most recent stock trade was executed by Gerald T Proehl on 8 August 2024, trading 1,666 units of TENX stock currently worth $6,131.

What does Tenax Therapeutics Inc do?

tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.

Complete history of Mr. Proehl stock trades at Ritter Pharmaceuticals, Tenax Therapeutics Inc és Sophiris Bio Inc

Tenax Therapeutics Inc executives and stock owners

Tenax Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael B. Jebsen CPA,
  Advisor
• Anthony A. DiTonno,
  CEO & Director
• Michael Jebsen,
  President, Chief Financial Officer
• Michael B. Jebsen,
  Pres & CFO
• Christopher T. Giordano,
  CEO, Pres & Director
• Ellen Corliss,
  Vice President, Corporate Communications & Investor Relations
• Chris Rallis,
  Independent Director
• Gregory Pepin,
  Independent Director
• Gerald Proehl,
  Director
• James Mitchum,
  Director
• Keith Maher,
  Director
• Steven Boyd,
  Director
• Paula Bokesch,
  Chief Medical Officer
• Doug Randall,
  Executive Vice President - Business and Commercial Operations
• Douglas Hay,
  Executive Vice President - Regulatory Affairs
• Anthony DiTonno,
  Chief Executive Officer, Director
• Ronald Blanck,
  Independent Chairman of the Board
• Eliot M. Lurier CPA,
  Interim Chief Financial Officer
• Dr. Stuart Rich M.D.,
  Chairman of Scientific Advisory Board, Chief Medical Officer & Director
• Nancy J. M. Hecox,
  Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
• John P Kelley,
  Chief Executive Officer
• Michael H. Davidson,
  
• Declan Doogan,
  
• Stuart Rich,
  Chief Medical Officer
• June Sherie Almenoff,
  
• Robyn Hunter,
  
• Christopher Thomas Giordano,
  CEO